Journal
CURRENT HEMATOLOGIC MALIGNANCY REPORTS
Volume 8, Issue 4, Pages 299-306Publisher
CURRENT MEDICINE GROUP
DOI: 10.1007/s11899-013-0184-z
Keywords
Myeloproliferative neoplasms; JAK2; Clonal evolution; Oncogene; Tumor suppressor; Hematologicmalignancy
Categories
Funding
- Austrian Science Fund [P23257-B12]
- MPN Research Foundation
- Austrian Science Fund (FWF) [P23257] Funding Source: Austrian Science Fund (FWF)
- Austrian Science Fund (FWF) [P 23257] Funding Source: researchfish
Ask authors/readers for more resources
The clonal blood disorders polycythemia vera, essential thrombocythemia and primary myelofibrosis belong to the BCR-ABL1-negative myeloproliferative neoplasms and are specified by increased production of terminally differentiated myeloid cells. Clonal evolution, disease initiation and progression are influenced by genetic alterations, often affecting cytokine signaling and gene expression. This review outlines somatic changes discovered in myeloproliferative neoplasms and how these genetic aberrations influence the pathogenesis of myeloproliferative neoplasms. Furthermore, genetic responses to drug treatments in myeloproliferative neoplasms are discussed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
